Simplex Castings Q2 FY27: standalone PAT up 37% YoY to ₹7.64 Cr, OPM expands to 20.2%
PAT +36.98% YoY · revenue +13.71% · margins expanding
₹63.01 Cr
+13.71% YoY
₹7.64 Cr
+36.98% YoY
12.1%
+2.1pp YoY
₹1.86
Simplex Castings' standalone PAT rose 36.98% year-on-year to ₹7.64 Cr on revenue of ₹63.01 Cr (+13.71% YoY), with sequential moves far milder at +3.38% revenue and +11.41% PAT QoQ — the YoY print is what matters here since this is a small industrial-castings business without meaningful seasonality. As a micro-cap with no analyst coverage, there is no formal Street consensus to grade the print against; a web search turned up no brokerage estimates for this quarter, so vsStreet is genuinely unknown rather than assumed.
Q2 FY-2027 vs prior quarters
Profitability improved on both margin lines: operating margin (OPM) expanded to 20.23% from 17.42% a year ago and 18.89% last quarter, while net margin (NPM) rose to 12.13% from 10.00% YoY and 11.24% QoQ. The expansion sits mainly on the materials line — raw-material consumption plus inventory movement came to ₹43.13 Cr versus ₹38.85 Cr a year earlier on 13.7% higher revenue, a sub-proportionate rise — while employee and other operating costs scaled roughly in line with revenue. Management's FY27 guidance from the Q1 concall called for ₹300 Cr revenue and ~11-12% NPM; H1FY27 revenue of ₹123.96 Cr is 41% of that target and Q2's 12.13% NPM sits at the top of the guided band, so the quarter reads as on-plan to slightly ahead, not a blowout beat or a miss.
The stock went into the print at ₹135.7, up 3% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 3 consecutive quarters; revenue is at a 6-quarter high.
FY27 revenue target ₹300 Cr on track (₹60 Cr done in Q1, ₹150+ Cr order book); railways to target ₹50 Cr, power ₹100 Cr. Margins to remain ~11-12% NPM. FY28 target ₹500 Cr (requires organic 300-350 + inorganic growth). Working capital to improve from ~120 days to 60-70 days by FY28 through product mix shift.
— This quarter: met
The quarter's other newsflow is capital-raise and management-continuity rather than operating. The company allotted equity/warrants worth ₹8.0 Cr (Nov 6) and a further ₹18.69 Cr (Nov 12), days after BSE's in-principle approval for the preferential issue (Nov 3); paid-up capital rose to ₹8.20 Cr from ₹7.77 Cr a year ago and weighted-average shares grew 5.5% YoY, which is why EPS growth (+30% YoY on the split-adjusted ₹1.43 base) trails PAT growth. The proceeds line up with capital work-in-progress nearly tripling to ₹36.77 Cr from ₹12.38 Cr at FY26-end — consistent with the capacity build management has said it needs to reach its FY28 ₹500 Cr target (requiring organic growth to ₹300-350 Cr plus inorganic additions). Separately, CFO Rajesh Kumar Acharya's medical-grounds resignation (Nov 7) was withdrawn and accepted back at the same Nov 13 board meeting that approved these results, closing out a week of uncertainty with no continuity gap.
W1
H2FY27 needs ~₹176 Cr of revenue (vs ₹124 Cr in H1) to hit management's ₹300 Cr FY27 target — a ~42% half-on-half step-up.
W2
Execution against the ₹130+ Cr order book flagged at the Q1FY27 call, and progress on management's ₹50 Cr railways and ₹100 Cr power segment targets.
W3
NPM sustainability near the top of management's guided 11-12% band (12.13% in Q2) as the capex-funded capacity build (CWIP at ₹36.77 Cr) comes online.
Unaudited standalone only, no consolidated statement in this filing. The 'Profit before exceptional items and tax' row has its Q2FY27/Q1FY27 values transposed in the source table (confirmed via tax-expense cross-check against the correctly-ordered PBT and PAT rows, which tie out exactly). YoY EPS isn't directly comparable to our DB record (₹7.42) because a 1:5 stock split (FV ₹10→₹2) approved in Q1FY27 was applied retrospectively; the split-adjusted year-ago EPS per this filing is ₹1.43. No exceptional items in either the current or year-ago quarter, so no adjusted-PAT distinction is needed.